Sativex® is a cannabinoid medicine for the treatment of spasticity due to multiple sclerosis which is also in development in cancer pain and neuropathic pain of various origins.
GW has now entered into five separate licensing agreements for Sativex® – with Bayer HealthCare in the UK and Canada; Almirall in Europe (excluding the UK) and Mexico; Otsuka Pharmaceutical Co. Ltd in the United States; Novartis in the Middle East (excluding Israel), Africa, and Asia (excluding China and Japan); and with Neopharm in Israel.
Sativex® is made by gw-pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange,. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group’s lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy.
About Us Overview
About Us Overview. Retrieved from http://www.gwpharm.com/about-us-overview.aspx